Howard S Hochster, MD

Professor of Medicine (Medical Oncology); Associate Director for Clinical Sciences, Yale Cancer Center; Clinical Program Leader, Gastrointestinal Cancers Program, Smilow Cancer Hospital; Clinical Research Program Leader, Gastrointestinal Cancers Program, Yale Cancer Center

Clinical Interests

  • Esophageal Neoplasms
  • Gastrointestinal Neoplasms
  • Pancreatic Neoplasms
  • Stomach Neoplasms
  • Colorectal Neoplasms

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Gastrointestinal Cancer Program

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Clinical Trials

Conditions Study Title
Colon E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Unknown Sites An Investigation of Tumor-Derived Mutated DNA in the Blood and Urine as a Biomarker for Cancer Treatment Response
Colon C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Esophagus RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma {CIRB}
Colon 19F-MRS (Magnetic Resonance Spectroscopy) Studies of in-vivo 5-Fluorouracil Pharmacokinetics with and without Bevacizumab in Patients with Liver Metastases from Adenocarcinoma of the colon
Colon A Phase II Multi-center, Randomized, Placebo-Controlled Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer
Esophagus Yale Gastrointestinal Cancer Biorepository
Rectum KD018: Pilot Trial of KD018 with Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients with Locally Advanced Rectal Cancer
Melanoma, skin Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies
Pancreas Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS
Pancreas S1313: A Phase Ib/II Randomized Study of Modified FOLFIRINOX +Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma.
Colon S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Unknown Sites Tumor Molecular Profiling
Pancreas A phase 3, multicenter, open-label, randomized study of nab-Paclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma
Pancreas A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Esophagus, Other Digestive Organ A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors
Colon, Rectum A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.
Colon A Pilot study of the Role of Omalizumab (Xolair) in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction (HSR)
Other Skin A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

Edit this profile

Contact Info

Howard S Hochster, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 8

New Haven, CT 06510
Mailing Address
333 Cedar Street
Box 208028

New Haven, CT 06039

Curriculum Vitae